XOMA and LVTX Related Headlines
Go Back- XOMA completes acquisition of LAVA Therapeutics for $1.04 per share
- XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
- LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
- XOMA and LAVA amend purchase agreement with lower cash offer
- XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
- XOMA extends LAVA acquisition tender offer to October 17
- XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
- XOMA Royalty to acquire LAVA Therapeutics for up to $1.24 per share
- XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
XOMA and LVTX Related Press Releases
Go Back- XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
- LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
- XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
- XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
- XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
